ABSTRACT UK-14,304 [5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)-6-quinoxalinamine]-mediated vasodilator responses were studied on wire myograph-mounted mouse aorta to determine the cells involved, mechanisms of action, and subtypes of ␣ 2 -adrenoceptors. In the presence of induced tone, UK-14,304 produced concentration-related vasodilatation that was abolished by rauwolscine, N -nitro-L-arginine methyl ester (L-NAME), or endothelium removal, indicating that endothelial ␣ 2 -adrenoceptors can release nitric oxide. In the ␣ 2A -adrenoceptor knockout mouse and the D79N mouse, a functional knockout of the ␣ 2A -adrenoceptor, these relaxant effects of UK-14,304 were lost, indicating the involvement of the ␣ 2A -adrenoceptor. UK-14,304 could also contract aorta: a small contraction occurred at high concentrations, was enhanced by L-NAME, and was absent in the ␣ 1D -adrenoceptor knockout mouse, indicating activation of the ␣ 1D -adrenoceptor. There was no evidence for a contractile ␣ 2 -adrenoceptor-mediated response. A fluorescent ligand, quinazoline piperazine bodipy, antagonized the relaxant action of UK-14,304. This compound could be visualized on aortic endothelial cells, and its binding could be prevented by rauwolscine, providing direct evidence for the presence of ␣ 2 -adrenoceptors on the endothelium. Norepinephrine reduced tone in the ␣ 1D -adrenoceptor knockout and controls, an effect blocked by rauwolscine and L-NAME but not by prazosin. This suggests that norepinephrine activates endothelial ␣ 2 -adrenoceptors. In conclusion, the endothelium of mouse aorta has an ␣ 2A -adrenoceptor that responds to norepinephrine; promotes the release of nitric oxide, causing smooth muscle relaxation; and that can be directly visualized. Knockout or genetic malfunction of this receptor should increase arterial stiffness, exacerbated by raised catecholamines, and contribute to heart failure.
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All three ␣ 2 -adrenoceptors have distinct, yet poorly defined, roles in the control of the vascular system. The limited selectivity of agonists and antagonists has therefore prompted the use of transgenic mouse models. The subtypes are ␣ 2A , ␣ 2B , and ␣ 2C : the mouse ortholog of the human ␣ 2A -adrenoceptor is sometimes called the ␣ 2D -or ␣ 2A/D -adrenoceptor; we use the generic term ␣ 2A -adrenoceptor (Alexander et al., 2004) . They have two direct pharmacological effects on blood vessels that can modify vascular tone: a direct vasopressor action (for review, see Wilson et al., 1991; Guimaraes and Moura, 2001 ) and vasodilatation via endothelium-derived relaxant factors (Cocks and Angus, 1983; Vanhoutte, 2001) . They also reduce sympathetic traffic centrally and inhibit transmitter release from sympathetic postganglionic nerves (Starke, 2001) , although this is not well established as a physiological phenomenon in blood vessels. Available pharmacological data and knockout studies, although not definitive, present evidence for, at least, ␣ 2A -, ␣ 2B -, and ␣ 2C -adrenoceptors for vasoconstriction, ␣ 2A -and ␣ 2C -adrenoceptors for sympatho-inhibition, and ␣ 2A -adrenoceptors for endothelial vasodilatation, although none of the relevant studies has considered all three actions, and each chooses a different example preparation (Bockman et al., 1996; Link et al., 1996; Hein et al., 1999; McCafferty et al., 1999; Chotani et al., 2000; Guimaraes and Moura, 2001; Vanhoutte, 2001) .
Thus, there is no consensus for the ␣ 2 -adrenoceptor subtypes responsible for direct vascular actions, constrictor or dilator. Yet, both phenomena are potentially significant for the therapeutic use of ␣ 2 -adrenoceptor agonists and antagonists and for the physiological and pathophysiological roles of ␣ 2 -adrenoceptors in the cardiovascular system.
A pathophysiological role for ␣ 2 -adrenoceptors has recently emerged from the demonstration that polymorphisms of ␣ 2A -and ␣ 2C -adrenoceptors are linked with cardiovascular disease (Brede et al., 2002; Small et al., 2002) . Hypotheses for the etiology have focused almost exclusively on the concept that malfunction of ␣ 2 -adrenoceptors regulating the release of neurotransmitters from sympathetic nerves could be deleterious to the cardiovascular system. However, this could just as rationally be attributable to endothelial ␣ 2 -adrenoceptors. The first specific clinical implication is that synergistic polymorphisms of ␤ 1 -and ␣ 2C -adrenoceptors, a combination over-represented in the American population of African descent, can increase the risk of congestive heart failure (Small et al., 2002 (Small et al., , 2004 . Since interpretation of this etiology involves the use of genetically modified mice (Brede et al., 2002; Liggett, 2004) , it is timely to elucidate the mechanisms underlying vascular ␣ 2 -adrenoceptors using this species to establish the physiological and hence potential pathophysiological roles of the different ␣ 2 -adrenoceptor subtypes and to determine whether endothelial ␣ 2 -adrenoceptors need to be considered.
There is also controversy surrounding whether the initial step in the release of endothelial relaxant factors is direct activation of receptors on the endothelial cells or indirectly through activation of receptors on smooth muscle cells that then signal to the endothelium via myo-endothelial connections (Dora, 2001) . This is compelling since it is consistent with previous vascular localization of receptors by autoradiography, which indicated ␣ 2 -adrenoceptors in the medial layer but not on endothelium (Stephenson and Summers, 1987) .
Analysis of ␣ 2 -adrenoceptors in the aorta is complicated by the presence of a powerful ␣ 1 -adrenoceptor-mediated contraction, even when using relatively selective agonists. Vandeputte et al. (2003) showed that, in mouse aorta, the complex response to norepinephrine contains constrictor ␣ 1D -and dilator ␣ 2A -adrenoceptor components acting in opposition. This factor was accounted for by isolating the ␣ 2 -adrenoceptor-mediated response in a strain of mice in which the dominant contractile adrenoceptor in this vessel, ␣ 1D -adrenoceptor (Daly et al., 2002) , was knocked out (Tanoue et al., 2002) . "␣ 2 -Adrenoceptor-selective" agonists are often partial agonists at ␣ 1 -adrenoceptors (Docherty and McGrath, 1980; Wilson et al., 1991) .
The objectives of the present study were to establish the vasodilator phenotype for ␣ 2 -adrenoceptors in mouse large arteries; identify by two independent transgenic models whether the ␣ 2A -adrenoceptor subtype is involved; establish the functional involvement of the endothelium and nitric oxide; determine whether the receptors are located on the endothelium; and demonstrate that the phenomenon is activated by a physiological agonist, norepinephrine.
We demonstrate that ␣ 2A -adrenoceptors can account for the entire ␣ 2 -adrenoceptor-mediated vasodilator response in mouse aorta. A combination of pharmacology, transgenic models, and fluorescent ligand binding shows that the site is on the endothelial cells and that the mechanism involves the ␣ 2A -adrenoceptor subtype, which activates the release of endothelial nitric oxide.
Materials and Methods

Experimental Rationale
Rings of aorta mounted on a wire myograph ensured minimal disruption to endothelium. A previous study of mouse aorta found no evidence for ␣ 2 -adrenoceptor-mediated vasodilatation (Russell and Watts, 2000) but used strips, which are susceptible to endothelial damage (Furchgott and Zawadski, 1980) .
Receptor "knockout" strains were used to simplify pharmacological interpretation where nonselectivity of drugs limits analysis. These were the ␣ 2A -adrenoceptor knockout mouse and mice harboring the D79N point mutation of the ␣ 2A -adrenoceptor, which serves as a "functional knockout" in some systems due to low expression of the mutant receptor and dysfunction due to disengagement of G protein-coupling to potassium but not calcium currents (Surprenant et al., 1992; Ceresa and Limbird, 1994; MacMillan et al., 1996 MacMillan et al., , 1998 .
Aortic contraction, by agonists, is a confounding factor. We eliminated this using the ␣ 1D -adrenoceptor knockout (Tanoue et al., 2002) .
Finally, we set out to make a direct visual demonstration of endothelial ␣ 2 -adrenoceptors using a fluorescent ligand. Proof of specificity of binding was complicated by the unexpected demonstration of endothelial ␣ 1 -adrenoceptors: this was overcome by using the knockout of the ␣ 1B -adrenoceptor (Cavalli et al., 1997) and selective antagonists of the ␣ 1A -adrenoceptor and ␣ 1D -adrenoceptor subtypes. Concentrations of these drugs were selected, from pharmacological analysis of ␣ 1A -and ␣ 1D -adrenoceptor-mediated responses in these same vessels, to be clearly (approximately 10-fold) above the affinity constant for the desired receptor but below that for the others (Daly et al., 2002) . We showed that 0.1 M QAPB antagonized the ␣ 2 -adrenoceptor-mediated relaxation to UK-14,304 before using this concentration to visualize ␣ 2 -adrenoceptors on the vascular endothelium.
Myography
Male mice (4 months old) were killed by CO 2 inhalation. Descending thoracic aortae were isolated and set up in Krebs' on wire myographs with 5-ml baths to which drugs were added directly, as described previously (Daly et al., 2002) . Strains were ␣ 2A -adrenoceptor mutant D79N mouse (MacMillan et al., 1996 (MacMillan et al., , 1998 , backcrossed onto C57/BL6 (gift from Professor Lee Limbird, Vanderbilt University, Nashville, TN); ␣ 2A -adrenoceptor knockout C57/BL6 (␣ 2A/Dknockout; The Jackson Laboratory, Bar Harbor, ME) (gift from Professor J. R. Docherty, Royal College of Surgeons in Ireland, Dublin, Ireland); ␣ 1D -adrenoceptor knockout (Tanoue et al., 2002) , background of 129sv/C57/BL6 (gift from Professor Gozoh Tsujimoto, Faculty of Pharmaceutical Sciences, Kyoto University, Kyoto, Japan); and ␣ 1B -adrenoceptor knockout (Cavalli et al., 1997) background of 129sv/C57/BL6 (gift from Professor Susanna Cotecchia, Université de Lausanne, Lausanne, Switzerland). We compared several aspects of adrenergic pharmacology between 129sv/C57/BL6 controls and the C57/BL6 without finding significant differences. Thus, in this study we used the 129sv/C57/BL6 as control. jpet.aspetjournals.org norepinephrine, 0.1 M acetylcholine was added to assess endothelial integrity. Criteria for functional and dysfunctional endothelium were, respectively, Ͼ50 and Ͻ5% relaxation at start and finish of experiment. N -Nitro-L-arginine methyl ester (L-NAME) (0.1 mM) abolished relaxation to acetylcholine.
Tissues were tested with increasing cumulative concentrations of UK-14,304 in 0.5 log unit increments from 1 nM to 30 M. After a 60-min rest period, test drugs were added for at least 30 min before construction of a second cumulative concentration-response curve.
Visualization of Endothelial ␣ 2 -Adrenoceptors
We used the fluorescent ligand QAPB, an analog of prazosin with high affinity for ␣ 1 -adrenoceptors (pK i ϭ 8.1-8.9) (McGrath et al., 1996; Daly et al., 1998; Mackenzie et al., 2000) but that also has moderate affinity for ␣ 2 -adrenoceptors (pK i ϭ 7.3-7.8; Dr. C. M. Milligan, personal communication; method of Brown et al., 1993) . Binding to the three ␣ 1 -adrenoceptors was eliminated by using vessels from the ␣ 1B -adrenoceptor-knockout mouse and blocking the other two subtypes with selective antagonists: for ␣ 1A -adrenoceptors, 5-methylurapidil, (5MeU); and for ␣ 1D -adrenoceptors, BMY7378. This allowed us to visualize putative ␣ 2 -adrenoceptors. We then confirmed that they were ␣ 2 -adrenoceptors by preventing this binding with rauwolscine.
Laser Scanning Confocal Microscopy
Tissue Preparation. Segments (2-3 mm) of aorta from ␣ 1B -knockout mice were incubated for 30 min in 0.1 M BMY7378 and 0.1 M 5MeU, with or without 0.1 M rauwolscine, and then 0.1 M QAPB was added for 60 min. After incubation, without washing, aortic segments were cut open and placed endothelial side up in the sample well of a slide sealed with a glass coverslip (thickness no. 1.5).
Image Capture. Serial optical sections were collected on a BioRad 1024 and Radiance 2100 confocal laser scanning microscope. Excitation/emission 488/515 nm for QAPB. Laser power, gain, and offset (contrast and brightness) were kept constant. Tissues were visualized using a 40ϫ oil immersion objective numerical aperture 1.00 and therefore optimal pinhole setting 1.5. Image size 512 ϫ 512 pixels equates to a field size of 289 ϫ 289 m. Each procedure was carried out in triplicate on at least three different mice. 
Drugs
Statistics
Values are means Ϯ standard error of the mean from n experiments. Differences in maximal contraction response to agonist in the presence and absence of drugs were compared using one-way analysis of variance or by Student's t test. Statistical and graphical analysis was carried out using Excel 97 (Microsoft, Redmond, WA) and GraphPad Prism 3.00 (GraphPad Software Inc., San Diego, CA).
Results
␣ 2 -Adrenoceptor-Mediated Relaxation. Rings were preconstricted with a concentration of U-46619 required to produce ϳ75% of the maximum contraction. At the preconstriction plateau, 1 M UK-14,304 was added, causing a marked rapid fall in tone (vasodilatation; Fig. 1a) . UK-14,304-induced relaxations were blocked in the presence of rauwolscine (Fig. 1b) but not prazosin (Fig. 1c) .
The cumulative concentration-response curve for the ␣ 2 -adrenoceptor agonist UK-14,304 versus U-46619 preconstriction had two phases (Fig. 2a) . UK-14,304 produced vasodilator responses at low concentrations (1 nM-0.3 M) and vasoconstriction at higher (Ͼ0.3 M) concentrations. In aorta taken from either ␣ 2A -knockout or D79N mice, the vasodilator response was not present (Fig. 2a) .
Removal of the endothelium also abolished the vasodilator response to low concentrations of UK-14,304 (Fig. 2b) , confirming the likely involvement of ␣ 2 -adrenoceptors on the endothelium. In aorta, from ␣ 1D -knockout mice, the vasoconstrictor effect of high concentrations of UK-14,304 was absent (Fig. 2b) .
In a separate series of experiments, a single concentration of 1 M UK-14,304 was tested against 1 to 10 nM U-46619 in the presence and absence of the nitric oxide synthase inhibitor L-NAME (0.1 mM). In control tissues, UK-14,304 produced a reduction in tone (7.4 Ϯ 4.7%; n ϭ 7). In the presence of L-NAME, UK-14,304 produced an increase in tone (44.2 Ϯ 0.7%; n ϭ 7).
Localization of ␣ 2 -Adrenoceptors in Aortic Endothelial Cells. QAPB (0.1 M), a fluorescent ␣-adrenoceptor ligand, inhibited UK-14,304-induced relaxation of mouse aorta ( Fig. 3a; p Ͻ 0.001). To visualize QAPB binding to ␣ 2 -adrenoceptor sites, the three ␣ 1 -adrenoceptor subtypes were first eliminated by using the ␣ 1B -adrenoceptor-knockout mouse and incubating vessels in the ␣ 1D -adrenoceptor antagonist BMY7378 (0.1 M) and the ␣ 1A -adrenoceptor antagonist 5MeU (0.1 M). Confocal fluorescence microscopy revealed 0.1 M QAPB binding to endothelial cells, which line the grooves of the (unpressurized) internal elastic lamina (Fig. 3,  b and c) . In the presence of 0.1 M rauwolscine, no QAPB binding could be detected (Fig. 3d) .
Norepinephrine-Induced Vasodilatation. Experiments were performed in the presence of either ␤-blockade (0.1 M propranolol) alone or ␤-blockade and ␣ 1 -blockade (0.1 M prazosin) to determine the physiological significance of the ␣ 2 -adrenoceptor-mediated vasodilatation. In the presence of preconstrictor U-46619, ␤-blockade and in the absence of the ␣ 1D -adrenoceptors, 1 M norepinephrine produced a marked vasodilatation (Fig. 4a ). Norepinephrine's vasodilator effect was blocked in the presence of 0.1 mM L-NAME (Fig. 4b) . In control mice, after ␤-blockade and ␣ 1 -blockade, 1 M norepinephrine caused a relaxation of U-46619-induced tone (Fig. 4c) . In aorta taken from D79N mice, the vasodilator action of norepinephrine was also absent (Fig. 4d) . In ␣ 1D -knockout aorta, after ␤-blockade, 0.1 M rauwolscine significantly inhibited the norepinephrine-induced relaxation ( Fig. 4e ; p Ͻ 0.0001, unpaired t test).
Discussion
This study has established a vasodilator phenotype for ␣ 2 -adrenoceptors in the mouse that involves nitric oxide release of endothelial origin. The ␣ 2A -adrenoceptor subtype alone is responsible with no evidence for a residual response by another subtype after its elimination. Having established the properties of the phenomenon using the selective synthetic agonist UK-14,304, we demonstrated that the physiological ligand for the receptors, norepinephrine, was highly effective once its other actions had been eliminated. Since conducting arteries are not (or are sparsely) innervated, but the endothelial cells are in intimate contact with the plasma, we propose that circulating catecholamines inhibit tone (stiffness) of these vessels via endothelial ␣ 2A -adrenoceptors and that dysfunction of this action would exacerbate vasoconstrictor factors, causing an increased load on the heart. The aortic phenotype of the vasodilator ␣ 2 -adrenoceptor contrasts with the prejunctional ␣ 2 -adrenoceptor in that only one subtype, the ␣ 2A -adrenoceptor, was responsible, whereas both ␣ 2A -and ␣ 2C -adrenoceptors were implicated in the prejunctional modulation of norepinephrine release, and both had to be knocked out to eliminate that response . There was no evidence of compensatory upregulation of another ␣ 2 -adrenoceptor subtype.
The ability to focus on the ␣ 2A -adrenoceptor-activated, endothelium/NO-mediated vasodilator response in the mouse and other model species should accelerate appreciation of its role in humans. Endothelial ␣ 2 -adrenoceptors have not been reported in humans, but we can find no evidence of this having been pursued.
The endothelial ␣ 2 -adrenoceptors should be considered as possible physiological players since they are activated by norepinephrine. The correct function of ␣ 2A -adrenoceptors may be essential to regulation of blood flow in critical vascular beds, in the face of a generalized sympathetic activation in "fight or flight", e.g., nitric oxide released by ␣ 2 -adrenoceptors protects the kidney from excessive adrenergic vasoconstriction (Zou and Cowley, 2000) . Norepinephrine and epinephrine both circulate freely in the plasma and have intimate contact with endothelial cells. In our demonstration that natural ligands can activate endothelial ␣ 2 -adrenoceptors, we used norepinephrine rather than epinephrine to avoid activating vasodilatory ␤-adrenergic receptors. All evidence points to similar potency of these two catecholamines at ␣ 2 -adrenoceptors.
Pharmacological analysis of vasodilator responses via ␣ 2 -adrenoceptors was simplified by the use of selective agonists and receptor knockouts. Aorta had relaxation as its most sensitive response to UK-14,304, and this was susceptible to endothelial removal or inhibition of NOS. This represents the conducting artery vasodilator phenotype of the ␣ 2A -adrenoceptor since it was absent in the knockout and the D79N mutation of this receptor. The loss of the response in both of these strains strengthens the case. It produces definitive evidence that an endothelial ␣ 2 -adrenoceptor response is mediated via the ␣ 2A -adrenoceptor and validates the pharmacological analysis in large arteries of the pig (Bockman et al., 1996) of an endothelial ␣ 2A -adrenoceptor subtype.
The effect of UK-14,304 in the ␣ 1D -adrenoceptor-knockout mouse was interesting because, by eliminating the contractile response, the entire concentration response curve for vasodilatation was isolated.
We visualized the fluorescent ligand QAPB binding to aortic endothelial cells and eliminated this binding with the archetypal ␣ 2 -adrenoceptor antagonist rauwolscine. We validated this by showing that this fluorescent ligand is a functional antagonist of aortic relaxation to UK-14,304 at the concentration used for visualization. This provides compel- Fig. 2 . Concentration-response curves for UK-14,304 in aorta taken from various mouse strains. a, comparison of the effect of UK-14,304 in control (wild type) (E; n ϭ 6), ␣ 2A -adrenoceptor-knockout (F; n ϭ 5), and D79N mice (‚; n ϭ 6). b, comparison of the effect of UK-14,304 alone (E; n ϭ 6), in the absence of endothelium (F; n ϭ 5), or in aorta taken from ␣ 1D -knockout mice (‚; n ϭ 7). at ASPET Journals on April 6, 2017 jpet.aspetjournals.org ling direct evidence for the endothelial location of the ␣ 2 -adrenoceptors that mediate vasodilatation. This direct proof of ␣ 2 -adrenoceptor binding sites on endothelial cells suggests that earlier autoradiography, which indicated no endothelial binding of tritiated rauwolscine (Stephenson and Summers, 1987) , provided a false negative result due to the small volume of endothelial tissue to which radioligand can bind, coupled with the low receptor expression level on endothelium relative to a high level in the arterial media. We now show that ␣ 2 -adrenoceptors are located on the endothelium.
Demonstrating that a natural ligand, norepinephrine, could activate the endothelial ␣ 2 -adrenoceptors was straightforward once the confounding factors had been clarified using the selective agonist, antagonists, and knockout strains. Norepinephrine produces, in vitro, a powerful contractile response that overwhelms its vasodilator actions. Its relaxant endothelial ␣ 2 -adrenoceptor-mediated effect could be seen clearly in the ␣ 1D -adrenoceptor-knockout and was shown to be rauwolscine sensitive. Demonstrating that the receptor involved is the ␣ 2A -adrenoceptor is more difficult since the ␣ 1D -adrenoceptor is present in the ␣ 2A -adrenoceptor knockout strains. However, comparing the normal mouse with the D79N in the presence of prazosin and propranolol, it was possible to show the complete absence of a dilator response in D79N in contrast to a relaxant or multiphasic response in normal mice. Together with the other evidence this strongly supports that norepinephrine activates vasodilator ␣ 2A -adrenoceptors.
A peripheral endothelium/nitric oxide-mediated direct vasodilatation to ␣ 2 -adrenoceptor agonists must now be considered as a potential depressor mechanism to intravenous ␣ 2 -adrenoceptor agonists in addition to any centrally mediated sympatho-inhibitory effects or prejunctional inhibition of postganglionic sympathetic transmission. We suggest that emphasis on the latter action should be reconsidered. Deletion or mutation of the ␣ 2A -adrenoceptors eliminates the reduction in heart rate and blood pressure caused by intravenous ␣ 2 -adrenoceptor agonists such as UK-14,304 and clonidine in the conscious mouse (MacMillan et al., 1996; Altman et al., 1999) . This has been assumed to arise entirely from withdrawal of sympathetic tone, although no evidence for a change in sympathetic tone is available. There is also no evidence for prejunctional ␣ 2 -adrenoceptors on mouse vascular sympathetic nerves. In the pithed rat, the vascular response to sympathetic nerve stimulation was the least sensitive of several organ systems to inhibition by clonidine (Docherty and McGrath, 1980) . Thus, if the mouse is like the rat, inhibition of norepinephrine release from nerve endings in blood vessels may not be a major action of ␣ 2 -adrenoceptor agonists. In conducting arteries, vasodilatation via endothelial ␣ 2 -adrenoceptors would reduce blood pressure via a reduced after-load. Thus, there may be an endothelial component to the vasodepressor action of ␣ 2 -adrenoceptor activation, and this may combine with any sympatho-inhibition that exists.
Large artery endothelial ␣ 2 -adrenoceptors should be relevant to the hypothesis that ␣ 2A -adrenoceptors confer protection from heart failure (Brede et al., 2002) . Excess mortality in the ␣ 2A -adrenoceptor-knockout strain was attributed to heart failure due to a combination of enhanced left ventricular hypertrophy, fibrosis, and elevated circulating catecholamines (Brede et al., 2002) . The present work predicts that in the ␣ 2A -adrenoceptor-knockout the loss of large artery vasodilatation via ␣ 2A -adrenoceptors combined with unopposed vasoconstriction to elevated catecholamines would create a highly deleterious situation of reduced arterial compliance and consequent increased cardiac work. Lack of innervation makes it unlikely that sympatho-inhibition has a role and likely that the endothelial ␣ 2A -adrenoceptor effect will be responsible.
The ␣ 2C -adrenoceptor-knockout mouse is susceptible to a similar pathology (Brede et al., 2002) . Combined with the link between the polymorphisms of this receptor and susceptibility to heart failure (Small et al., 2002) , this has focused attention on this receptor. The present work indicates that ␣ 2C -adrenoceptors are not involved in mouse large artery endothelial vasodilatation and the lack of innervation excludes sympatho-inhibition, so there is no evidence for a vasodilator action by this subtype in large arteries. However, ␣ 2C -adrenoceptors could be involved in innervated small arteries that regulate blood pressure through the peripheral resistance, either through endothelial or nerve mechanisms. Thus, heart failure may be exacerbated by different mechanisms according to which ␣ 2 -adrenoceptor is "abnormal". 
